Pfizer In Year-End Drug-Licensing Push | January 3, 2011 Issue - Vol. 89 Issue 1 | Chemical & Engineering News
Volume 89 Issue 1 | p. 12 | Concentrates
Issue Date: January 3, 2011

Pfizer In Year-End Drug-Licensing Push

Department: Business
Keywords: Monoclonal antibody, peptide, vaccine

San Diego-based Lpath has granted Pfizer an exclusive option to license iSONEP, a monoclonal antibody being evaluated for the treatment of ophthalmology disorders, including wet age-related macular degeneration. Pfizer will pay Lpath $14 million and share the cost of iSONEP’s Phase I and II clinical trials. Lpath is eligible for milestone payments of as much as $497.5 million. Pfizer has also entered an agreement with Australia’s Phylogica to discover peptide-based vaccines using Phylogica’s peptide drug discovery platform. Pfizer will pay $500,000 up front and could make clinical and other milestone payments of as much as $134 million.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment